HRP20170794T1 - Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a - Google Patents
Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a Download PDFInfo
- Publication number
- HRP20170794T1 HRP20170794T1 HRP20170794TT HRP20170794T HRP20170794T1 HR P20170794 T1 HRP20170794 T1 HR P20170794T1 HR P20170794T T HRP20170794T T HR P20170794TT HR P20170794 T HRP20170794 T HR P20170794T HR P20170794 T1 HRP20170794 T1 HR P20170794T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- peptide
- preparation
- subject
- factor viii
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 16
- 229960000301 factor viii Drugs 0.000 title claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 201000003542 Factor VIII deficiency Diseases 0.000 title claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000013633 acquired hemophilia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Peptid koji sadrži FVIII-izvedenu sekvencu DNIMVTFRNQASRPY, te navedeni peptid
(a) ima formulu
XXGDNIMVTFRNQASRPYGXX
pri čemu X je ili Lizin ili glutaminska kiselina; i
(b) ima jednu od slijedećih sekvenci:
KKGDNIMVTFRNQASRPYGKK (SEQ ID No. 17)
KKGDNIMVTFRNQASRPYGKE (SEQ ID No. 18)
KKGDNIMVTFRNQASRPYGEK (SEQ ID No. 19)
KEGDNIMVTFRNQASRPYGKK (SEQ ID No. 25)
KEGDNIMVTFRNQASRPYGKE (SEQ ID No. 26)
KEGDNIMVTFRNQASRPYGEK (SEQ ID No. 27)
EKGDNIMVTFRNQASRPYGKK (SEQ ID No. 29)
EKGDNIMVTFRNQASRPYGKE (SEQ ID No. 30) i
EKGDNIMVTFRNQASRPYGEK (SEQ ID No. 31).
2. Peptid koji sadrži FVIII-izvedenu sekvencu PRCLTRYYSSFVNME, te navedeni peptid
(a) ima formulu
XXGPRCLTRYYSSFVNMEGXX
pri čemu X je ili Lizin ili glutaminska kiselina; i
(b) ima jednu od slijedećih sekvenci:
KKGPRCLTRYYSSFVNMEGKK (SEQ ID No. 1)
KKGPRCLTRYYSSFVNMEGKE (SEQ ID No. 2)
KKGPRCLTRYYSSFVNMEGEK (SEQ ID No. 3)
EEGPRCLTRYYSSFVNMEGKK (SEQ ID No. 5)
EEGPRCLTRYYSSFVNMEGEK (SEQ ID No. 7)
KEGPRCLTRYYSSFVNMEGKK (SEQ ID No. 9)
KEGPRCLTRYYSSFVNMEGKE (SEQ ID No. 10)
KEGPRCLTRYYSSFVNMEGEK (SEQ ID No. 11) i
EKGPRCLTRYYSSFVNMEGKK (SEQ ID No. 13).
3. Pripravak naznačen time da sadrži mnoštvo peptida, uključujući jedan ili više peptida prema zahtjevu 1 ili 2.
4. Pripravak prema zahtjevu 3, naznačen time da sadrži barem jedan peptid prema zahtjevu 1 i barem jedan peptid prema zahtjevu 2.
5. Pripravak prema zahtjevu 4, naznačen time da sadrži peptid koji ima SEQ ID No. 1 i peptid koji ima SEQ ID No. 17
6. Peptid prema zahtjevu 1 ili 2, ili pripravak prema bilo kojem od zahtjeva 3 do 5, naznačen time da je za uporabu za suzbijanje ili sprječavanje stvaranja inhibitorskih protutijela faktora VIII in vivo.
7. Peptid prema zahtjevu 1 ili 2, ili pripravak prema bilo kojem od zahtjeva 3 do 5, naznačen time da je za uporabu u postupku liječenja hemofilije kod subjekta.
8. Peptid ili pripravak za uporabu prema zahtjevu 7, naznačen time da subjekt ima hemofiliju A, i podvrgava se, ili uskoro će se podvrgnuti, zamjenskoj terapiji faktorom VIII i/ili prolaznoj terapiji sa FVIII.
9. Peptid ili pripravak za uporabu prema zahtjevu 7, naznačen time da subjekt ima, ili je u opasnosti od stjecanja stečene hemofilije.
10. Peptid ili pripravak za uporabu prema bilo kojem od zahtjeva 7 do 9, naznačen time da subjekt je HLA-DR2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220328.7A GB201220328D0 (en) | 2012-11-12 | 2012-11-12 | Peptides |
| GBGB1316660.8A GB201316660D0 (en) | 2013-09-19 | 2013-09-19 | Peptides |
| PCT/IB2013/060060 WO2014072958A1 (en) | 2012-11-12 | 2013-11-11 | Peptides |
| EP13795002.8A EP2917232B1 (en) | 2012-11-12 | 2013-11-11 | Factor viii-derived peptides for use in the treatment of haemophilia a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170794T1 true HRP20170794T1 (hr) | 2017-08-11 |
Family
ID=49627013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170794TT HRP20170794T1 (hr) | 2012-11-12 | 2017-05-28 | Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150306192A1 (hr) |
| EP (1) | EP2917232B1 (hr) |
| JP (1) | JP6247696B2 (hr) |
| KR (1) | KR102165486B1 (hr) |
| CN (1) | CN104903347B (hr) |
| AU (1) | AU2013343024B2 (hr) |
| BR (1) | BR112015010625B1 (hr) |
| CA (1) | CA2890835C (hr) |
| CY (1) | CY1119164T1 (hr) |
| DK (1) | DK2917232T3 (hr) |
| EA (1) | EA036483B1 (hr) |
| ES (1) | ES2626881T3 (hr) |
| HK (1) | HK1209138A1 (hr) |
| HR (1) | HRP20170794T1 (hr) |
| HU (1) | HUE033586T2 (hr) |
| IL (1) | IL238627B (hr) |
| IN (1) | IN2015DN03814A (hr) |
| LT (1) | LT2917232T (hr) |
| MX (1) | MX350777B (hr) |
| MY (1) | MY176708A (hr) |
| NZ (1) | NZ708812A (hr) |
| PH (1) | PH12015501033B1 (hr) |
| PL (1) | PL2917232T3 (hr) |
| PT (1) | PT2917232T (hr) |
| RS (1) | RS56069B1 (hr) |
| SG (1) | SG11201503657UA (hr) |
| SI (1) | SI2917232T1 (hr) |
| WO (1) | WO2014072958A1 (hr) |
| ZA (1) | ZA201503127B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018127830A1 (en) | 2017-01-04 | 2018-07-12 | Apitope International Nv | S-arrestin peptides and therapeutic uses thereof |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| GB201909774D0 (en) | 2019-07-08 | 2019-08-21 | Apitope Tech Bristol Limited | Method |
| WO2022063887A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for increasing the efficacy of factor viii replacement therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1311542B1 (en) | 2000-08-21 | 2008-07-16 | Apitope Technology (Bristol) Limited | Tolerogenic peptides |
| WO2002060917A2 (en) * | 2000-12-01 | 2002-08-08 | Regents Of The University Of Minnesota | Method to treat hemophilia |
| FR2842812A1 (fr) * | 2002-07-26 | 2004-01-30 | Pf Medicament | Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse |
| JP2006188507A (ja) * | 2004-12-10 | 2006-07-20 | Tokyo Univ Of Agriculture & Technology | 蛋白質の溶解度向上方法 |
| EP1945797B1 (en) * | 2005-10-28 | 2012-05-30 | Boehringer Ingelheim International GmbH | Hepatitis c virus ns2/3 activity assay |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| GB0801513D0 (en) * | 2008-01-28 | 2008-03-05 | Circassia Ltd | Peptides from factor VIII |
| GB0908515D0 (en) * | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| WO2011060371A2 (en) * | 2009-11-13 | 2011-05-19 | Puget Sound Blood Center | Factor viii t cell epitope variants having reduced immunogenicity |
| NZ609474A (en) * | 2010-10-27 | 2015-06-26 | Baxter Healthcare Sa | Fviii peptides for immune tolerance induction and immunodiagnostics |
-
2013
- 2013-11-11 NZ NZ708812A patent/NZ708812A/en unknown
- 2013-11-11 EP EP13795002.8A patent/EP2917232B1/en active Active
- 2013-11-11 BR BR112015010625-0A patent/BR112015010625B1/pt active IP Right Grant
- 2013-11-11 SI SI201330663A patent/SI2917232T1/sl unknown
- 2013-11-11 PL PL13795002T patent/PL2917232T3/pl unknown
- 2013-11-11 HU HUE13795002A patent/HUE033586T2/hu unknown
- 2013-11-11 ES ES13795002.8T patent/ES2626881T3/es active Active
- 2013-11-11 CA CA2890835A patent/CA2890835C/en active Active
- 2013-11-11 LT LTEP13795002.8T patent/LT2917232T/lt unknown
- 2013-11-11 CN CN201380069078.2A patent/CN104903347B/zh active Active
- 2013-11-11 MY MYPI2015001224A patent/MY176708A/en unknown
- 2013-11-11 IN IN3814DEN2015 patent/IN2015DN03814A/en unknown
- 2013-11-11 AU AU2013343024A patent/AU2013343024B2/en active Active
- 2013-11-11 MX MX2015005973A patent/MX350777B/es active IP Right Grant
- 2013-11-11 EA EA201590927A patent/EA036483B1/ru unknown
- 2013-11-11 PT PT137950028T patent/PT2917232T/pt unknown
- 2013-11-11 WO PCT/IB2013/060060 patent/WO2014072958A1/en active Application Filing
- 2013-11-11 JP JP2015541291A patent/JP6247696B2/ja active Active
- 2013-11-11 US US14/441,923 patent/US20150306192A1/en not_active Abandoned
- 2013-11-11 SG SG11201503657UA patent/SG11201503657UA/en unknown
- 2013-11-11 DK DK13795002.8T patent/DK2917232T3/en active
- 2013-11-11 RS RS20170542A patent/RS56069B1/sr unknown
- 2013-11-11 KR KR1020157012787A patent/KR102165486B1/ko active IP Right Grant
-
2015
- 2015-05-04 IL IL238627A patent/IL238627B/en active IP Right Grant
- 2015-05-07 ZA ZA2015/03127A patent/ZA201503127B/en unknown
- 2015-05-08 PH PH12015501033A patent/PH12015501033B1/en unknown
- 2015-10-07 HK HK15109790.6A patent/HK1209138A1/xx unknown
-
2017
- 2017-05-28 HR HRP20170794TT patent/HRP20170794T1/hr unknown
- 2017-05-31 CY CY20171100568T patent/CY1119164T1/el unknown
-
2021
- 2021-04-23 US US17/239,251 patent/US20210346476A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170794T1 (hr) | Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| EP3428182A3 (en) | Anti-inflammatory peptides and composition comprising the same | |
| EP3428181A3 (en) | Anti-inflammatory peptides and composition comprising the same | |
| ECSP14016014A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca | |
| EP2528934A4 (en) | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF | |
| HRP20140185T1 (hr) | Peptidi i njihova primjena | |
| GB201016733D0 (en) | Compounds and their use | |
| EA201200515A1 (ru) | Полипептиды и их применение | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| HRP20140344T4 (hr) | Fviii peptidi i njihova uporaba u lijeäśenju hemofilije | |
| EA201590329A1 (ru) | Использование полученных из pedf полипептидов для стимуляции регенерации или артериогенеза в мышцах или сухожилиях | |
| EA201490901A1 (ru) | Линкеры на основе тирозина для свободного соединения пептидов | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| TR201906685T4 (tr) | Kristalin macitentan içeren farmasötik bileşim. | |
| WO2014140103A3 (en) | Thrombin sensitive coagulation factor x molecules | |
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| AR087034A1 (es) | Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas | |
| HRP20141182T1 (hr) | Fviii-izvedeni peptidi i njihova upotreba za izazivanje tolerancije kod hemofiliäśara | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
| JP2017517561A5 (hr) | ||
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| PE20160877A1 (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion |